Comprehensive analysis of ETS family members in melanoma by fluorescence in situ hybridization reveals recurrent ETV1 amplification

Translational Oncology

Volumn 6, Issue 4, 2013, Pages 405-412

  Mehra, Rohit ^a   Dhanasekaran, Saravana M ^a   Palanisamy, Nallasivam ^a   Vats, Pankaj ^a   Cao, Xuhong ^a   Kim, Jung H ^a   Kim, David S L ^a   Johnson, Timothy ^a   Fullen, Douglas R ^a   Chinnaiyan, Arul M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; TRANSCRIPTION FACTOR ER81;

ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE FUSION; GENE LOCUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

EID: 84881060095     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13340     Document Type: Article

References (33)

1. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, and Garraway LA (2013). Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957-959.
2. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, et al. (2011). Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3, 111-121.
3. American Cancer Society (2008). Cancer Facts & Figures 2008. American Cancer Society, Atlanta, GA.
4. Garbe C and Leiter U (2009). Melanoma epidemiology and trends. Clin Dermatol 27, 3-9.
5. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, et al. (Eds.) (2009). In SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site.
6. Seth A and Watson DK (2005). ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41, 2462-2478.
7. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648.
8. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, et al. (2008). Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10, 177-188.
9. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566.
10. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, et al. (2010). Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16, 793-798.
11. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, and Chinnaiyan AM (2008). Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 68, 3584-3590.
12. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, et al. (2008). Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 68, 73-80.
13. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, et al. (2007). Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20, 538-544.
14. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, et al. (2006). TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66, 3396-3400.
15. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et al. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595-599.
16. Jane-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, Baker AC, Nazarian RM, Vijayendran KG, Sellers WR, et al. (2010). An onco-genic role for ETV1 in melanoma. Cancer Res 70, 2075-2084.
17. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, et al. (2008). A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 68, 7629-7637.
18. Janknecht R (2005). EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 363, 1-14.
19. Shin S, Bosc DG, Ingle JN, Spelsberg TC, and Janknecht R (2008). Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors. J Cell Biochem 105, 866-874.
20. Kurpios NA, Sabolic NA, Shepherd TG, Fidalgo GM, and Hassell JA (2003). Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia 8, 177-190.
21. Hocker TL, Singh MK, and Tsao H (2008). Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 128, 2575-2595.
22. E600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
23. V600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26, 1055-1069.
24. Pierotti MA, Tamborini E, Negri T, Pricl S, and Pilotti S (2011). Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol 8, 161-170.
25. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, et al. (2010). ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467, 849-853.
26. Hata H, Kitamura T, Higashino F, Hida K, Yoshida K, Ohiro Y, Totsuka Y, Kitagawa Y, and Shindoh M (2008). Expression of E1AF, an ets-oncogene transcription factor, highly correlates with malignant phenotype of malignant melanoma through up-regulation of the membrane-type-1 matrix metalloproteinase gene. Oncol Rep 19, 1093-1098.
27. Torlakovic EE, Slipicevic A, Florenes VA, Chibbar R, DeCoteau JF, and Bilalovic N (2008). Fli-1 expression in malignant melanoma. Histol Histopathol 23, 1309-1314.
28. Keehn CA, Smoller BR, and Morgan MB (2003). Expression of the ets-1 proto-oncogene in melanocytic lesions. Mod Pathol 16, 772-777.
29. Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N, and Bosserhoff AK (2004). The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci 61, 118-128.
30. De la Houssaye G, Vieira V, Masson C, Beermann F, Dufier JL, Menasche M, and Abitbol M (2008). ETS-1 and ETS-2 are upregulated in a transgenic mouse model of pigmented ocular neoplasm. Mol Vis 14, 1912-1928.
31. Torlakovic EE, Bilalovic N, Nesland JM, Torlakovic G, and Florenes VA (2004). Ets-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis. Mod Pathol 17, 1400-1406.
32. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, et al. (2011). Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664-678.
33. Park SR and Chen A (2012). Poly(adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. Hematol Oncol Clin North Am 26, 649-670, ix.